← Back to Clinical Trials
Recruiting NCT06819449

NCT06819449 Rab 32 Gene Polymorphisms as a Prognostic Factor in Leprosy Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06819449
Status Recruiting
Phase
Sponsor South Valley University
Condition Leprosy
Study Type INTERVENTIONAL
Enrollment 50 participants
Start Date 2024-12-20
Primary Completion 2025-12-10

Trial Parameters

Condition Leprosy
Sponsor South Valley University
Study Type INTERVENTIONAL
Phase N/A
Enrollment 50
Sex ALL
Min Age 5 Years
Max Age 60 Years
Start Date 2024-12-20
Completion 2025-12-10
Interventions
Dapsone

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Mycobacterium leprae is a slow-growing bacillus that causes leprosy. the infection may take two to ten years to incubate. While the exact mechanism of infection transmission is unknown, direct bacillus absorption through the nasal or respiratory mucosa and aerosolized nasal secretions are the most common theories. The bacteria is subsequently transported by the bloodstream to the peripheral nerves, where it can result in tissue damage from painless burns and ulcers as well as irreparable nerve damage that results in a loss of protective feeling.

Eligibility Criteria

Inclusion Criteria: * Patients of both sexes with positive slit skin smear for m.leprae . Exclusion Criteria: * Contraindications to Multi drug therapy : * Patients with hypersensitivity to sulfa . * Patients with hypersensitivity to clofazimine or rifampcin. * pregnant or lactating women.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology